Proposed MDR Reforms Raise Concerns Over Patient Safety in the EU
The European Commission has put forward significant amendments to the Medical Device Regulation (MDR) and the In-Vitro Diagnostic Regulation (IVDR), aiming to address long-standing structural challenges in the regulatory framework for medical devices across the European Union. These regulations determine the requirements that medical devices must meet to be approved for the EU market.
In late 2024, pressure from the European Parliament accelerated the reform process, citing the existing MDR as overly bureaucratic and burdensome, particularly for small and medium-sized enterprises (SMEs). Among the most resource-intensive requirements under the current system was the need for manufacturers to re-certify their medical devices every five years. This regular re-certification process, along with other obligations, was seen as a barrier to innovation and competitiveness in the sector. The Commission's latest proposal eliminates some of these requirements, signaling a shift to simpler compliance measures for manufacturers.
The draft reforms suggest easing obligations for periodic safety reports and simplifying reporting duties. The legislative process is expected to move swiftly, with a targeted completion date set for the end of 2027. The so-called trilogue negotiations between the European Commission, Parliament, and Council are scheduled for the spring of 2027, indicating an ambitious timeframe for finalizing the new regulations.
However, the proposed changes have raised concerns among regulatory bodies and industry stakeholders. Organizations representing notified bodies, such as the association for German Technical Inspection Agencies (TÜV), have expressed reservations about the potential impact on patient safety. These groups warn that loosening regulatory oversight could result in diminished safeguards for users of medical devices within the EU.
According to representatives from the German technical inspection sector, the proposed reduction in safety and reporting requirements could mean that flaws or risks associated with medical devices may only come to light after incidents occur. This marks a departure from the precautionary principle that has long guided EU health and safety policy. Under the new approach, issues such as infections, injuries, or defects in materials and manufacturing might be identified only after they have already affected patients, rather than being preemptively addressed through regular, unannounced audits and comprehensive safety assessments.
The magnitude of the MDR reform is significant, considering that the European Union represents a single market of 450 million people, making it one of the largest regulated patient populations globally. The scope of these changes is seen as comparable to major national health reforms, given the direct effect on access to and oversight of medical devices throughout the member states.
As the legislative process advances, stakeholders from across the healthcare, regulatory, and manufacturing sectors are closely monitoring the potential consequences of the proposed reforms. The balance between reducing administrative burdens for manufacturers and maintaining high standards of patient safety remains a central point of debate. The outcomes of the ongoing discussions and legislative negotiations will shape the regulatory landscape for medical devices in the EU for years to come.